Mr. Andre Larente reports

DIAGNOS ANNOUNCES A 3-YEAR CONTRACT WITH CIELO VISTA EYE CLINIC IN MEXICO

Diagnos Inc. has signed a three-year contract with Cielo Vista Eye Clinic. Diagnos will supply its CARA (computer-assisted retina analysis) platform and enable Cielo to screen its patients for diabetic macular edema and diabetic retinopathy.

Cielo is an ophthalmologic clinic located in the city of Jerez, state of Zacatecas, Mexico. Founded in 1996, Cielo specializes in comprehensive ophthalmic assessments, optometric services, treatment of eye diseases and microsurgeries, treating and serving over 16,000 patients per year. Cielo currently uses the Spanish version of Diagnos's CARA platform to screen its at-risk clients, such as diabetic patients.

"The Cielo Vista Eye Clinic is pleased to team up with Diagnos to assist in the automatic early detection of diabetes-related health issues. We have validated Diagnos's technology through a pilot project and are now pleased to use this technology full-time. This will assist us to care for a significantly increasing number of patients with avoidable blindness due to diabetes," said Dr. Maria Lopez Vitolas and Dr. Jesus Rodriguez Pinedo, ophthalmologists and founders of Cielo Vista Eye Clinic. "Cielo Vista Eye Clinic specializes in the diagnosis, treatment and monitoring of any type of visual problem; we use the most modern surgical techniques and technology to detect and correct vision problems, including diabetic retinopathy," concluded Dr. Lopez and Dr. Rodriguez.

"Our goal over the next three years to assist Cielo in becoming the national reference for early detection of diabetes-related eye issues. We are excited to embark on this journey in which we will actively support our partner in its daily operations to detect and treat diabetic retinopathy and macular edema. At Diagnos, it is our commitment to co-work with specialists and provide our AI platform to assist in identifying rapidly and accurately diverse pathologies that need to be treated or monitored. Diabetic retinopathy is a symptomless disease that can lead to blindness if not treated in its early stages," said Andre Larente, president of Diagnos.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the U.S. Food and Drug Administration (United States), CE (Europe), Cofepris (Mexico), and Saudi Food and Drug Administration (Saudi Arabia).

We seek Safe Harbor.